Cargando…
The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma
Yes Associated Protein 1 (YAP) and Transcriptional coactivator with PDZ-Binding Motif (TAZ) have gained notoriety for their ability to drive tumor initiation and progression in a wide variety of cancers, including melanoma. YAP and TAZ act as drivers of melanoma through its interaction with the TEAD...
Autores principales: | Lui, Jason W., Xiao, Sixia, Ogomori, Kelsey, Hammarstedt, Jon E., Little, Elizabeth C., Lang, Deborah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329844/ https://www.ncbi.nlm.nih.gov/pubmed/30662519 http://dx.doi.org/10.7150/jca.27472 |
Ejemplares similares
-
Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin
por: Brouwer, Niels J., et al.
Publicado: (2021) -
PAX3 and ETS1 synergistically activate MET expression in melanoma cells
por: Kubic, Jennifer D., et al.
Publicado: (2014) -
Photodynamic Therapy with Verteporfin for Corneal Neovascularization
por: Al-Torbak, Abdullah A.
Publicado: (2012) -
In vitro effects of verteporfin on ocular cells
por: Ammar, David A., et al.
Publicado: (2013) -
Anti-Cancer Activity of Verteporfin in Cholangiocarcinoma
por: Golino, Jihye L., et al.
Publicado: (2023)